Bliss Cunningham

I completed a PhD in 2018 from Monash University. My PhD studies focused on the development of a passive immunotherapeutic to prevent and treat Clostridium difficile infections, supported by Immuron Ltd. This work was presented at both national and international conferences, and resulted in a co-first author publication in Scientific Reports and inclusion on a patent that has been filed in Australia, Canada, Europe, USA, China and New Zealand. I’ve recently started a post-doctoral position with the McDevitt group, investigating the role of transition metal ions in pneumococcal infections.